文献速递系统性红斑狼疮

利妥昔单抗作为系统性红斑狼疮维持治疗:147例患者多中心观察研究

Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients.
PubMed 文献 · Arthritis Rheumatol · 2019-08-30

该多中心观察研究纳入147例接受利妥昔单抗诱导治疗的SLE患者,27%在6个月时治疗失败,低既往免疫抑制治疗次数和低C4水平降低失败风险。80例接受利妥昔单抗维持治疗(中位24.5个月),记录85次复发(主要为肌肉骨骼),35%患者无复发且损伤累积低;首次RTX时活动性关节病变与维持治疗期间复发风险相关(P=0.011),维持治疗后无复发生存与单疗程RTX相似(P=0.72)。

要点

  • 低既往免疫抑制治疗次数(P=0.034)和低C4水平(P=0.008)与6个月治疗失败风险降低相关。
  • 首次RTX时活动性关节病变与维持治疗期间复发风险相关(P=0.011)。
  • 维持治疗后无复发生存与单疗程RTX相似(P=0.72),复发风险仍高。

核心结论

  • 利妥昔单抗维持治疗是难治性SLE患者的潜在治疗选择,但维持治疗期间仍会复发,且维持治疗后复发风险高,与单疗程RTX后相当。

研究设计与样本

  • 欧洲4中心观察性研究,纳入147例接受利妥昔单抗诱导治疗的SLE患者,随访比较单疗程RTX与RTX维持治疗(RMT)的结局。

主要发现

  • 147例患者中27%在6个月时治疗失败。
  • 多因素分析显示低既往免疫抑制治疗次数(P=0.034)和低C4水平(P=0.008)降低治疗失败风险。
  • 80例接受RMT,中位24.5个月,记录85次复发(主要为肌肉骨骼),人均1.06次。
  • 首次RTX时活动性关节病变与RMT期间复发风险相关(P=0.011);RMT后无复发生存与单疗程RTX相似(P=0.72)。

临床怎么用

  • 对于难治性SLE患者,可考虑利妥昔单抗维持治疗,但需告知维持治疗期间仍可能复发。
  • 首次RTX时存在活动性关节病变的患者在维持治疗期间复发风险更高,应加强监测。
  • 维持治疗结束后复发风险仍高,需继续随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The efficacy of rituximab (RTX) in systemic lupus erythematosus (SLE) is a subject of debate. This study was undertaken to investigate the outcomes of RTX treatment in a European SLE cohort, with an emphasis on the role of RTX as a maintenance agent. METHODS: All patients with SLE who were receiving RTX as induction therapy in 4 centers were included. Patients who received a single course of RTX and those who received RTX maintenance treatment (RMT) were followed up after treatment. Disease flares during the follow-up period were defined as an increase in disease activity and the number or dose of immunosuppressive drugs. RESULTS: Of 147 patients, 27% experienced treatment failure at 6 months. In a multivariate analysis, a low number of previous immunosuppressive therapies (P = 0.034) and low C4 levels (P = 0.008) reduced the risk of treatment failure. Eighty patients received RMT over a median of 24.5 months during which 85 relapses, mainly musculoskeletal, were recorded (1.06 per patient). At the time of the last RTX course, 84% of the patients were in remission. Twenty-eight (35%) of 80 patients never experienced a flare during RMT and had low damage accrual. Active articular disease at the time of the first RTX administration was associated with a risk of flare during RMT (P = 0.011). After RMT, relapse-free survival was similar to that in patients receiving a single RTX course (P = 0.72). CONCLUSION: RMT is a potential treatment option for patients with difficult-to-treat disease. Relapses occur during RMT and are more likely in those with active articular disease at the time of the first RTX administration. Relapse risk after RMT remains high and apparently comparable to that seen after a single RTX course.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Cassia MA, Alberici F, Jones RB, et al. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients. Arthritis Rheumatol. 2019. PMID: 31102498. doi:10.1002/art.40932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。